Acadia, Allergan extend research agreement to 2008

By Ted A. Knutson

Washington, March 6 - Acadia Pharmaceuticals Inc. said it and Allergan Sales LLC have agreed to extend the research term of their 2003 collaboration pact by two years to March 27, 2008.

During the extended research term, the parties will focus joint research efforts in the area of pain, which will continue to support the parties' existing alpha adrenergic program. In addition, the parties may elect to pursue additional discovery activities in ophthalmic or other indications.

Acadia said it will receive unspecified additional research funding during the extended research term.

During the extension Allergan could exclusively license chemistry and related assets for up to three drug targets for development and commercialization. If Acadia grants Allergan such an exclusive license, Acadia would be eligible to receive license fees and milestone payments upon the successful achievement of agreed upon clinical and regulatory objectives.

San Diego-based Acadia is a biopharmaceutical company that develops treatments for central nervous system disorders.

Irvine, Calif.-based Allergan is a specialty pharmaceutical company.

The announcement was made in an 8-K filing with the Securities and Exchange Commission.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.